Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Berg, Joost H, Heemskerk, Bianca, van Rooij, Nienke, Gomez-Eerland, Raquel, Michels, Samira, van Zon, Maaike, de Boer, Renate, Bakker, Noor A M, Jorritsma-Smit, Annelies, van Buuren, Marit M, Kvistborg, Pia, Spits, Hergen, Schotte, Remko, Mallo, Henk, Karger, Matthias, van der Hage, Joris A, Wouters, Michel W J M, Pronk, Loes M, Geukes Foppen, Marnix H, Blank, Christian U, Beijnen, Jos H, Nuijen, Bastiaan, Schumacher, Ton N, Haanen, John B A G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406109/
https://www.ncbi.nlm.nih.gov/pubmed/32753545
http://dx.doi.org/10.1136/jitc-2020-000848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406109/
https://www.ncbi.nlm.nih.gov/pubmed/32753545
http://dx.doi.org/10.1136/jitc-2020-000848

Ejemplares similares